New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
06:41 EDTJNJSurgeon told by J&J sales rep of hip implant troubles, Bloomberg reports
A surgeon in Montana testified that he stopped using Johnson & Johnsonís (JNJ) ASR all-metal hip device eight months before the company recalled it because a sales rep warned about problems with the implant by, reports Bloomberg. Peter Wendt, testified that he implanted 76 ASRs, including one in Loren Kransky, 65, of Montana. Kranskyís lawsuit is the first of 10,000 to go to trial over claims that J&Jís DePuy unit defectively designed the 93,000 hips recalled in August 2010 and failed to warn of the risks. J&J, denies that it defectively designed the device or that it contributed to the health problems of Kransky. Reference Link
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 29, 2015
14:06 EDTJNJJ&J announces study findings of paliperidone palmitate published in JAMA
Subscribe for More Information
March 27, 2015
15:14 EDTJNJJohnson & Johnson not likely to buy Intuitive Surgical, says BofA/Merrill
Subscribe for More Information
09:59 EDTJNJJohnson & Johnson to collaborate with Google to advance surgical robots
Subscribe for More Information
06:46 EDTJNJContact lens makers, discounters battling over price setting, NY Times says
Subscribe for More Information
March 25, 2015
07:29 EDTJNJLeerink to hold booth tours
Leerink Booth Tours at AAOS 2015 will be held in Las Vegas on March 25-26.
March 24, 2015
13:24 EDTJNJContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
07:45 EDTJNJFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
March 23, 2015
09:03 EDTJNJLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 17, 2015
05:35 EDTJNJJohnson & Johnson to invest $10M in UK government fund to fight dementia
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use